From Functions to Decisions: The Structural Shift Leaders Are Making
As the life sciences industry enters a period of rapid transformation, leading pharma organizations are rethinking not just where work gets done, but where decisions get made.
Across commercial, medical, R&D, and technology, leaders are redesigning decision-making to bring authority closer to the work, enabling faster action, clearer accountability, and better use of enterprise expertise.
This shift is being shaped by the evolution of global operating models and the increasing complexity of enterprise decision-making. Authority is moving beyond traditional functional hierarchies and regional structures, while organizations are looking to reduce dependence on individual decision-makers and recurring governance rituals. At the same time, decisions increasingly cut across brand, analytics, technology, and operations, making clear ownership and seamless collaboration more important than ever. As enterprises rethink where work gets done and where critical capabilities should reside, they are also reexamining where decision authority should sit, and how it can move closer to the work.
Forward-looking organizations are responding by moving decision authority closer to the work, redesigning it around platforms, end-to-end processes, and clear decision ownership.
What you'll discover
- From Ritual to Design: Why the “7 AM call” model persists and how leading organizations are embedding expertise and decision logic into platforms rather than individuals.
- Five Shifts in Decision Architecture: The structural moves from functional reporting to enterprise alignment, process fragments to end-to-end decision chains, cost optimization to capital allocation, waiting for permission to shaping the question, and single-champion sponsorship to multi-sponsor ownership.
- The Decision-Rights Maturity Spectrum: Anonymized examples of organizations that have earned decision authority — and those still negotiating for it.
- AI as Organizational Glue: Why AI's opportunity extends beyond productivity to embedding institutional knowledge and decision logic into platforms.
Explore how leading organizations are redesigning decision rights around platforms rather than functions, and what that shift could mean for the future of global pharma.
